Predicting potential therapeutic targets and small molecule drugs for early-stage lung adenocarcinoma - 27/04/24
Abstract |
Lung cancer is a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) constituting the majority, and its main subtype being lung adenocarcinoma (LUAD). Despite substantial advances in LUAD diagnosis and treatment, early diagnostic biomarkers inadequately fulfill clinical requirements. Thus, we conducted bioinformatics analysis to identify potential biomarkers and corresponding therapeutic drugs for early-stage LUAD patients. Here we identified a total of 10 differentially expressed genes (DEGs) with survival significance through the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). Subsequently, we identified a promising small molecule drug, Aminopurvalanol A, based on the 10 key genes using the L1000FWD application, which was validated by molecular docking followed by in vivo and in vitro experiments. The results highlighted TOP2A, CDH3, ASPM, CENPF, SLC2A1, and PRC1 as potential detection biomarkers for early LUAD. We confirmed the efficacy and safety of Aminopurvalanol A, providing valuable insights for the clinical management of LUAD.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Four publicly available microarray datasets were screened and 10 key genes were identified after survival validation. |
• | Potential detection biomarkers for early stage LUAD patients: TOP2A, CDH3, ASPM, CENPF, SLC2A1 and PRC1. |
• | Homology modeling was performed for target proteins with undefined crystal structures. |
• | Validated the efficacy and safety of Aminopurvalanol A as a potential therapeutic for LUAD. |
Abbreviations : NSCLC, LUAD, DEGs, GEO, TCGA
Keywords : LUAD, bioinformatics analysis, molecular docking, biomarker, Aminopurvalanol A
Plan
Vol 174
Article 116528- mai 2024 Retour au numéro
Article précédent
- Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma
- Yanfei Hao, Jintao Yang, Dongxu Liu, Hong Zhang, Tongwen Ou, Li Xiao, Wen Chen
- Chrysin inhibits ferroptosis of cerebral ischemia/reperfusion injury via regulating HIF-1α/CP loop
- Jinfeng Shang, Jiakang Jiao, Jingyi Wang, Mingxue Yan, Qiannan Li, Lizha Shabuerjiang, Guijinfeng Huang, Qi Song, Yinlian Wen, Xiaolu Zhang, Kai Wu, Yiran Cui, Xin Liu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?